$RMD
RESMED INC Stock $rmd

$rmd Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000094381923000029 Filed on October 27, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$1.163B	$1.102B
YoY Change	12.48%	16.0%
Cost Of Revenue	$515.9M	$502.3M
YoY Change	13.62%	22.66%
Gross Profit	$646.9M	$600.1M
YoY Change	11.6%	10.96%
Gross Profit Margin	55.64%	54.44%
Selling, General & Admin	$222.2M	$222.9M
YoY Change	4.95%	14.92%
% of Gross Profit	34.34%	37.14%
Research & Development	$73.88M	$75.71M
YoY Change	5.73%	19.82%
% of Gross Profit	11.42%	12.62%
Depreciation & Amortization	$44.78M	$44.93M
YoY Change	18.58%	23.88%
% of Gross Profit	6.92%	7.49%
Operating Expenses	$371.8M	$311.1M
YoY Change	24.14%	17.35%
Operating Profit	$275.1M	$289.0M
YoY Change	-1.82%	4.81%
Interest Expense	-$14.95M	-$19.45M
YoY Change	211.8%	56.36%
% of Operating Profit	-5.44%	-6.73%
Other Income/Expense, Net	-$15.64M	-$16.81M
YoY Change	140.5%	20.51%
Pretax Income	$259.5M	$272.2M
YoY Change	-5.2%	3.97%
Income Tax	$50.65M	$52.77M
% Of Pretax Income	19.52%	19.39%
Net Earnings	$208.8M	$219.4M
YoY Change	-7.16%	4.25%
Net Earnings / Revenue	17.96%	19.91%
Basic Earnings Per Share	$1.42	$1.49
Diluted Earnings Per Share	$1.42	$1.49
COMMON SHARES
Basic Shares Outstanding	147.1M shares	147.1M shares
Diluted Shares Outstanding	147.5M shares	147.5M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$210.2M	$209.1M
YoY Change	-16.96%	0.94%
Cash & Equivalents	$210.2M	$209.1M
Short-Term Investments
Other Short-Term Assets	$179.6M	$161.7M
YoY Change	21.83%	28.17%
Inventory	$933.2M	$958.2M
Prepaid Expenses
Receivables	$729.7M	$692.4M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$2.378B	$2.305B
YoY Change	2.28%	13.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$551.7M	$534.0M
YoY Change	5.55%	9.56%
Goodwill	$2.862B	$2.812B
YoY Change	3.42%	45.04%
Intangibles
YoY Change
Long-Term Investments	$66.09M	$62.16M
YoY Change	3.1%	687.85%
Other Assets	$275.8M	$265.1M
YoY Change	6.02%	52.86%
Total Long-Term Assets	$4.527B	$4.436B
YoY Change	4.05%	41.11%
TOTAL ASSETS
Total Short-Term Assets	$2.378B	$2.305B
Total Long-Term Assets	$4.527B	$4.436B
Total Assets	$6.905B	$6.741B
YoY Change	3.43%	30.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$202.4M	$177.0M
YoY Change	3.26%	-2.44%
Accrued Expenses	$332.1M	$348.3M
YoY Change	6.4%	7.47%
Deferred Revenue	$148.9M	$146.7M
YoY Change	11.19%	35.61%
Short-Term Debt	$9.898M	$9.905M
YoY Change	-0.02%	-0.01%
Long-Term Debt Due	$9.898M	$9.905M
YoY Change	-0.02%	-0.01%
Total Short-Term Liabilities	$764.1M	$770.8M
YoY Change	4.28%	11.28%
LONG-TERM LIABILITIES
Long-Term Debt	$1.217B	$1.352B
YoY Change	-32.05%	72.07%
Other Long-Term Liabilities	$72.89M	$34.33M
YoY Change	44.05%	488.01%
Total Long-Term Liabilities	$1.659B	$1.720B
YoY Change	-24.76%	63.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$764.1M	$770.8M
Total Long-Term Liabilities	$1.659B	$1.720B
Total Liabilities	$2.423B	$2.490B
YoY Change	-17.52%	42.74%
SHAREHOLDERS EQUITY
Retained Earnings	$4.540B	$4.402B
YoY Change	15.81%	17.08%
Common Stock	$1.823B	$1.791B
YoY Change	6.56%	5.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.482B	$4.250B
YoY Change
Total Liabilities & Shareholders Equity	$6.905B	$6.741B
YoY Change	3.43%	30.19%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	$208.8M	$219.4M
YoY Change	-7.16%	4.25%
Depreciation, Depletion And Amortization	$44.78M	$44.93M
YoY Change	18.58%	23.88%
Cash From Operating Activities	$272.8M	$286.3M
YoY Change	112.1%	541.0%
INVESTING ACTIVITIES
Capital Expenditures	$24.56M	$30.04M
YoY Change	-177.55%	3.37%
Acquisitions		$103.2M
YoY Change		440.23%
Other Investing Activities	-$16.58M	-$108.1M
YoY Change	-98.33%	309.01%
Cash From Investing Activities	-$41.14M	-$149.0M
YoY Change	-95.99%	153.34%
FINANCING ACTIVITIES
Cash Dividend Paid		$70.60M
YoY Change		9.57%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$185.0M
YoY Change		516.67%
Cash From Financing Activities	-239.0M	-$151.1M
YoY Change	-125.61%	260.87%
NET CHANGE
Cash From Operating Activities	272.8M	$286.3M
Cash From Investing Activities	-41.14M	-$149.0M
Cash From Financing Activities	-239.0M	-$151.1M
Net Change In Cash	-7.269M	-$18.79M
YoY Change	-120.69%	-71.76%
FREE CASH FLOW
Cash From Operating Activities	$272.8M	$286.3M
Capital Expenditures	$24.56M	$30.04M
Free Cash Flow	$248.3M	$256.2M
YoY Change	54.88%	1541.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Derivative Asset Current Statement Of Financial Position Extensible Enumeration DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2023Q2	us-gaap	Derivative Asset Current Statement Of Financial Position Extensible Enumeration DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2023Q2	us-gaap	Derivative Asset Noncurrent Statement Of Financial Position Extensible Enumeration DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q3	us-gaap	Derivative Asset Noncurrent Statement Of Financial Position Extensible Enumeration DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q3	us-gaap	Derivative Liability Noncurrent Statement Of Financial Position Extensible Enumeration DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q2	us-gaap	Derivative Liability Noncurrent Statement Of Financial Position Extensible Enumeration DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q3	us-gaap	Derivative Liability Current Statement Of Financial Position Extensible Enumeration DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q2	us-gaap	Derivative Liability Current Statement Of Financial Position Extensible Enumeration DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1102321000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	950294000	usd
CY2023Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	493353000	usd
CY2022Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	403110000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8908000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6374000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	502261000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	409484000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	600060000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	540810000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	222874000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	193933000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	75710000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	63188000	usd
CY2023Q3	rmd	Amortization Of Acquired Intangible Assets1 AmortizationOfAcquiredIntangibleAssets1	12479000	usd
CY2022Q3	rmd	Amortization Of Acquired Intangible Assets1 AmortizationOfAcquiredIntangibleAssets1	7950000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	311063000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	265071000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	288997000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	275739000	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-14957000	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-7134000	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3895000	usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2028000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-602000	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-3280000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2648000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1504000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-16806000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13946000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	272191000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	261793000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52769000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	51315000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	219422000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	210478000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.49
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.44
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.49
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.43
CY2023Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.48
CY2022Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.44
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	147075000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146431000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	147486000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	147134000	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	219422000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	210478000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-17093000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-30527000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-93381000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	171802000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	117097000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4129903000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	983000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-225000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	18510000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-47620000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	219422000	usd
CY2023Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.48
CY2023Q3	us-gaap	Dividends Dividends	70597000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	4250376000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	3360751000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2610000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-59000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	16919000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-93381000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	210478000	usd
CY2022Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.44
CY2022Q3	us-gaap	Dividends Dividends	64431000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	3432887000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	219422000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	210478000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	44934000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	36273000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	8508000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	7761000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	18510000	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	16919000	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3895000	usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2028000	usd
CY2023Q3	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-602000	usd
CY2022Q3	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-3280000	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6534000	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	56238000	usd
CY2023Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-26911000	usd
CY2022Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	147096000	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	42015000	usd
CY2022Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	36784000	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1018000	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8041000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	286283000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	44662000	usd
CY2023Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	30035000	usd
CY2022Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29056000	usd
CY2023Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10831000	usd
CY2022Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3317000	usd
CY2023Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	103183000	usd
CY2022Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	19100000	usd
CY2023Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	3680000	usd
CY2022Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	4291000	usd
CY2023Q3	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	250000	usd
CY2022Q3	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	usd
CY2023Q3	us-gaap	Payments For Proceeds From Derivative Instrument Investing Activities PaymentsForProceedsFromDerivativeInstrumentInvestingActivities	1501000	usd
CY2022Q3	us-gaap	Payments For Proceeds From Derivative Instrument Investing Activities PaymentsForProceedsFromDerivativeInstrumentInvestingActivities	3042000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-148980000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-58806000	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	983000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2610000	usd
CY2023Q3	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	225000	usd
CY2022Q3	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	59000	usd
CY2023Q3	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1293000	usd
CY2022Q3	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	105000000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	50000000	usd
CY2023Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	185000000	usd
CY2022Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	30000000	usd
CY2023Q3	us-gaap	Payments Of Dividends PaymentsOfDividends	70597000	usd
CY2022Q3	us-gaap	Payments Of Dividends PaymentsOfDividends	64431000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-151132000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-41880000	usd
CY2023Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-4962000	usd
CY2022Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-10523000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18791000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-66547000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	227891000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	273710000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	209100000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	207163000	usd
CY2023Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	76749000	usd
CY2022Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	53437000	usd
CY2023Q3	us-gaap	Interest Paid Net InterestPaidNet	14957000	usd
CY2022Q3	us-gaap	Interest Paid Net InterestPaidNet	7134000	usd
CY2023Q3	rmd	Noncash Part Of Acquisition Fair Value Of Assets Acquired NoncashPartOfAcquisitionFairValueOfAssetsAcquired	34092000	usd
CY2022Q3	rmd	Noncash Part Of Acquisition Fair Value Of Assets Acquired NoncashPartOfAcquisitionFairValueOfAssetsAcquired	9506000	usd
CY2023Q3	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	5325000	usd
CY2022Q3	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	3975000	usd
CY2023Q3	rmd	Goodwill Acquired During Period Increase Decrease GoodwillAcquiredDuringPeriodIncreaseDecrease	74416000	usd
CY2022Q3	rmd	Goodwill Acquired During Period Increase Decrease GoodwillAcquiredDuringPeriodIncreaseDecrease	19281000	usd
CY2023Q3	rmd	Deferred Payment Obligations For Acquisitions DeferredPaymentObligationsForAcquisitions	0	usd
CY2022Q3	rmd	Deferred Payment Obligations For Acquisitions DeferredPaymentObligationsForAcquisitions	-2856000	usd
CY2023Q3	rmd	Business Acquisition Contingent Consideration Recognized Liability BusinessAcquisitionContingentConsiderationRecognizedLiability	-1293000	usd
CY2022Q3	rmd	Business Acquisition Contingent Consideration Recognized Liability BusinessAcquisitionContingentConsiderationRecognizedLiability	2856000	usd
CY2023Q3	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	104476000	usd
CY2022Q3	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	19100000	usd
CY2023Q3	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023Q3	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	22700000	usd
CY2022Q3	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	23700000	usd
CY2023Q3	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1102321000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	950294000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	44934000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	36273000	usd
CY2023Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	427860000	usd
CY2023Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	459126000	usd
CY2023Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5190000	usd
CY2023Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3956000	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	525183000	usd
CY2023Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	534930000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	958233000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	998012000	usd
CY2023Q3	us-gaap	Prepaid Taxes PrepaidTaxes	104710000	usd
CY2023Q2	us-gaap	Prepaid Taxes PrepaidTaxes	114009000	usd
CY2023Q3	rmd	Prepaid Inventory PrepaidInventory	178490000	usd
CY2023Q2	rmd	Prepaid Inventory PrepaidInventory	143084000	usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	161664000	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	179925000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	444864000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	437018000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1201818000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1205868000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	667833000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	668012000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	533985000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	537856000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	563278000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	552341000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	2770299000	usd
CY2023Q3	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	74416000	usd
CY2023Q3	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-32573000	usd
CY2023Q3	us-gaap	Goodwill Goodwill	2812142000	usd
CY2023Q3	rmd	Marketable Equity Investments Fair Value MarketableEquityInvestmentsFairValue	11821000	usd
CY2023Q2	rmd	Marketable Equity Investments Fair Value MarketableEquityInvestmentsFairValue	12423000	usd
CY2023Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	69678000	usd
CY2023Q2	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	68748000	usd
CY2023Q3	us-gaap	Equity Method Investments EquityMethodInvestments	62161000	usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	65366000	usd
CY2023Q3	rmd	Equity Investments Total By Measurement Category EquityInvestmentsTotalByMeasurementCategory	143660000	usd
CY2023Q2	rmd	Equity Investments Total By Measurement Category EquityInvestmentsTotalByMeasurementCategory	146537000	usd
CY2023Q2	rmd	Equity Investments EquityInvestments	146537000	usd
CY2023Q3	rmd	Additional Equity Investments AdditionalEquityInvestments	3680000	usd
CY2023Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-602000	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3895000	usd
CY2023Q3	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-1810000	usd
CY2023Q3	rmd	Equity Investments EquityInvestments	143660000	usd
CY2022Q2	rmd	Equity Investments EquityInvestments	58375000	usd
CY2022Q3	rmd	Additional Equity Investments AdditionalEquityInvestments	4291000	usd
CY2022Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-3280000	usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2028000	usd
CY2022Q3	rmd	Equity Investments EquityInvestments	57358000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-600000	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-3300000	usd
CY2023Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	27621000	usd
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	25889000	usd
CY2023Q3	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	6025000	usd
CY2022Q3	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	2088000	usd
CY2023Q3	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	4828000	usd
CY2022Q3	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	2612000	usd
CY2023Q3	us-gaap	Standard And Extended Product Warranty Accrual Foreign Currency Translation Gain Loss StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss	672000	usd
CY2022Q3	us-gaap	Standard And Extended Product Warranty Accrual Foreign Currency Translation Gain Loss StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss	1272000	usd
CY2023Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	28146000	usd
CY2022Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	24093000	usd
CY2023Q3	rmd	Short Term Debt Gross ShortTermDebtGross	10000000	usd
CY2023Q2	rmd	Short Term Debt Gross ShortTermDebtGross	10000000	usd
CY2023Q3	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	95000	usd
CY2023Q2	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	98000	usd
CY2023Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	9905000	usd
CY2023Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	9902000	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1355000000	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1435000000	usd
CY2023Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	3489000	usd
CY2023Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	3766000	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	1351511000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	1431234000	usd
CY2023Q3	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	1361416000	usd
CY2023Q2	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	1441136000	usd
CY2023Q3	rmd	Debt To Consolidated Ebitda Ratio DebtToConsolidatedEbitdaRatio	3.50
CY2023Q3	rmd	Line Of Credit Facility Collateral Percentage Of Company LineOfCreditFacilityCollateralPercentageOfCompany	0.10
CY2023Q3	us-gaap	Senior Notes SeniorNotes	500000000	usd
CY2023Q2	us-gaap	Senior Notes SeniorNotes	500000000	usd
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	417364000	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	113167000	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	219422000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	210478000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	147075000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146431000	shares
CY2023Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	411000	shares
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	703000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	147486000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	147134000	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.49
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.44
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.49
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.43
CY2022Q2	rmd	Number Of Patents NumberOfPatents	8	patent
CY2023Q3	rmd	Receivables Sold With Limited Recourse ReceivablesSoldWithLimitedRecourse	47700000	usd
CY2022Q3	rmd	Receivables Sold With Limited Recourse ReceivablesSoldWithLimitedRecourse	39900000	usd
CY2023Q3	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	28900000	usd
CY2023Q3	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	800000	usd
CY2023Q2	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	32600000	usd
CY2022Q2	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	600000	usd
CY2023Q3	us-gaap	Derivative Assets DerivativeAssets	4328000	usd
CY2023Q2	us-gaap	Derivative Assets DerivativeAssets	2405000	usd
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	52847000	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	70699000	usd
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000943819-23-000029-index-headers.html	Edgar Link	pending
0000943819-23-000029-index.html	Edgar Link	pending
0000943819-23-000029.txt	Edgar Link	pending
0000943819-23-000029-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rmd-20230930.htm	Edgar Link	pending
rmd-20230930.xsd	Edgar Link	pending
rmd-20230930xex311.htm	Edgar Link	pending
rmd-20230930xex312.htm	Edgar Link	pending
rmd-20230930xex32.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rmd-20230930_cal.xml	Edgar Link	unprocessable
rmd-20230930_def.xml	Edgar Link	unprocessable
rmd-20230930_lab.xml	Edgar Link	unprocessable
rmd-20230930_pre.xml	Edgar Link	unprocessable
rmd-20230930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RMD
RESMED INC Stock $rmd

2023 Q4 Form 10-Q Financial Statement

#000094381923000029 Filed on October 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMD RESMED INC Stock $rmd

2023 Q4 Form 10-Q Financial Statement

#000094381923000029 Filed on October 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMD
RESMED INC Stock $rmd